Drugs / INO-8000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02772003 | Jun 2016 → Mar 2020 overdue | hepatitis C virus infection, hepatocellular carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-8000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02772003 ↗ |
| Route | Intramuscular | “Patients receive INO-8000 intramuscularly (IM)” NCT02772003 ↗ |